Apolipoprotein C-III
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).
Also Known As:
Apo C-III; Apo C-III-2; ApoC-III; Apolipoprotein C-III-0; Apolipoprotein C-III-1; Apolipoprotein CIII; Sialyl Apo C-III; Sialyl Apolipoprotein C-III; Apo C III; Apo C III 2; Apo C-III, Sialyl; ApoC III; Apolipoprotein C III; Apolipoprotein C III 0; Apolipoprotein C III 1; Apolipoprotein C-III, Sialyl; Sialyl Apo C III; Sialyl Apolipoprotein C III
Networked: 542
relevant articles (23 outcomes,
75 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Sacks, Frank M:
24 articles
(12/2021 - 04/2003)
|
2. | Chan, Dick C:
13 articles
(12/2021 - 08/2002)
|
3. | Watts, Gerald F:
13 articles
(12/2021 - 08/2002)
|
4. | Furtado, Jeremy D:
12 articles
(01/2021 - 04/2012)
|
5. | Barrett, P Hugh R:
12 articles
(10/2015 - 08/2002)
|
6. | Jensen, Majken K:
11 articles
(01/2021 - 04/2012)
|
7. | Taskinen, Marja-Riitta:
10 articles
(01/2022 - 06/2005)
|
8. | Olivieri, Oliviero:
9 articles
(01/2021 - 09/2002)
|
9. | Witztum, Joseph L:
8 articles
(01/2022 - 07/2015)
|
10. | Martinelli, Nicola:
8 articles
(01/2021 - 12/2003)
|
Related Diseases
Related Drugs and Biologics
Related Therapies and Procedures